Sickle Cell Disease (SCD)
Sickle cell disease is an inherited hemoglobinopathy characterized by the presence of hemoglobin S (HbS). Under low oxygen conditions, red blood cells sickle, leading to hemolysis, vaso-occlusion, and multi-organ damage. Early comprehensive care reduces mortality and improves life expectancy.
Genotypes
- HbSS (sickle cell anemia) – most severe
- HbSC, HbS/β⁰-thalassemia, HbS/β⁺-thalassemia
- Other rare variants (HbSD, HbSE)
Symptoms & Complications
- Vaso-occlusive pain crises (bones, chest, abdomen)
- Acute chest syndrome (fever, respiratory symptoms, pulmonary infiltrate)
- Chronic hemolytic anemia (fatigue, jaundice)
- Infections (functional asplenia), stroke, avascular necrosis, leg ulcers
- Kidney disease, retinopathy, priapism, pregnancy complications
- Psychosocial burdens, chronic pain, opioid exposure
Diagnosis & Screening
- Newborn screening (heel prick)
- Hemoglobin electrophoresis or HPLC to confirm genotype
- Regular monitoring: CBC, reticulocyte count, LDH, bilirubin, ferritin
- Transcranial Doppler ultrasound for stroke risk (ages 2–16)
- Ophthalmology exams (starting at age 10), echocardiograms, renal labs
Treatment & Management
Disease-Modifying Therapies
- Hydroxyurea: increases HbF, reduces crises, improves survival
- L-glutamine, voxelotor (improves hemoglobin), crizanlizumab (anti-P-selectin) for select patients
- Chronic transfusions or exchange transfusions for stroke prevention
- Pain management plans (NSAIDs, opioids, adjuvant agents), hydration, oxygen, infection treatment
- Antibiotic prophylaxis (penicillin) in young children; vaccinations (pneumococcal, meningococcal, Hib, influenza, COVID-19, RSV if eligible)
Curative Options
- Allogeneic hematopoietic stem cell transplant (HSCT) from matched donor
- Emerging gene therapy/editing with autologous hematopoietic stem cells (CRISPR-Cas9, lentiviral vectors) to reactivate HbF or correct HbS mutation
Supportive Care
- Manage chronic pain with multidisciplinary teams, mental health support
- Monitor for iron overload; chelation therapy if transfusion-dependent
- Education on trigger avoidance (cold, dehydration, high altitude)
Living with SCD
- Keep a symptom diary (pain crises, triggers, hydration, medications)
- Carry pain/action plans and hospital summaries
- Ensure rapid access to emergency care for fever >101°F or acute chest symptoms
- Maintain nutrition, hydration, and sleep
- Engage in moderate exercise; avoid extreme exertion or overheating
- Support groups and advocacy organizations help navigate disability and stigma
Research & Future Directions
Gene therapy/editing, anti-inflammatory agents, new HbF inducers, and digital health tools to forecast crises are rapidly evolving.
Experimental & Emerging Treatments
- CRISPR-Based Gene Editing (exa-cel): Reactivates fetal hemoglobin by editing BCL11A enhancers.
- Base Editing & Prime Editing: Precise correction of the HbS mutation.
- Anti-Inflammatory/Anti-Adhesion Therapies: Target neutrophil, platelet, and endothelial interactions to prevent vaso-occlusion.
- Digital Twin Crisis Prediction: AI models integrating wearables, environment, and labs to predict impending VOCs.
Track SCD with Diagnoza.care
Stay Ahead of Crises – Log pain episodes, triggers, hydration, transfusions, medications, vaccinations, labs, imaging, and specialist visits; capture side effects; and let the AI companion alert you when patterns signal a looming VOC or organ complication.
Medical Disclaimer: Informational only. Work with your hematologist or comprehensive sickle cell center for evidence-based therapy, curative options, and personalized crisis plans.
Sources: American Society of Hematology, Centers for Disease Control and Prevention, Sickle Cell Disease Association of America